biocon
biocon inaugurated biocon biopharmaceuticals, india' s largest multi - product biologics facility at biocon park .
biocon board meeting of biocon limited scheduled on wednesday, january 24, 2018 .
syngene inaugurated its new research centre at biocon' s new facility biocon park .
biocon said that its wholly - owned subsidiary, biocon research ltd, has ...
biocon divests enzymes division for usd 115 million to novozymes. biocon business portfolio to focus on biopharmaceuticals
glassdoor has 1 biocon reviews submitted anonymously by biocon employees. read employee reviews and ratings on glassdoor to decide if biocon is right for you .
1998—unilever agrees to sell its shareholding in biocon to the indian promoters. biocon becomes an independent entity
unilever acquired 50% of the shares in bcz by acquiring the entire shareholding of biocon biochemicals limited, ireland and biocon limited, ireland. unilever also acquired shares in biocon from biocon biochemicals limited, ireland and biocon limited, ireland and others .
biocon divests enzymes division for usd 115 million to novozymes. biocon business portfolio to focus on biopharmaceuticals .
does biocon limited require background check? what kind of background check does biocon limited d ...
biocon took its leadership role in the field of biotechnology forward to establish the biocon academ... .
biocon india is incorporated as a joint venture between biocon biochemicals ltd. of ireland and an indian entrepreneur, kiran mazumdar–shaw
29 november 1978—biocon india is incorporated as a joint venture between biocon biochemicals ltd. of ireland and kiran mazumdar - shaw .
biocon ltd. stock price, share price, live bse / nse, biocon ltd. bids offers. buy / sell biocon ltd. news & tips, & f & o; quotes
biocon acquires stake of its cuban partner cimab s. a. in their seven year old jv, biocon biopharmaceuticals pvt. ltd
biocon india is incorporated as a joint venture between biocon biochemicals ltd. of ireland and an indian entrepreneur, kiran mazumdar - shaw
collaboration partner: biocon limited co - development collaboration in which biocon and vaccinex jointly discover, develop and commercialize therapeutic antibody products .
biocon and bentley announce approval and expansion of bentley' s nasulin phase ii studies in india. biocon' s clinigene to conduct clinical trials .
biocon foundation recognized by who - india the csr arm of biocon has been awarded the public health champion award 2015 by the world health organization .
bqil (biocon quest india limited) was established with biocon and unilever acquiring around 50% stake each. bqil commenced manufacturing operations from august 1996 .
icici ventures and its affiliate funds were inducted as shareholders of biocon by way of subscription to 15. 35% of the share capital of biocon .
# highlightinvestment today # cash # premium and # biocon news cash premium call: sell biocon 633 targets 624 / 614 / 600. 00 stoploss 643
1989—unilever plc. acquires biocon biochemicals ltd. in ireland and merges it with its subsidiary, quest international; biocon receives us funding for proprietary technologies .
biocon ltd (bse code: 532523, nse: biocon), asia' s premier biopharmaceuticals company, announced its q4 & fy16 results today .
glassdoor is your resource for information about the health care & insurance benefits at biocon. learn about biocon health care & insurance, including a description from the employer, and comments and ratings provided anonymously by current and former biocon employees .
biocon was the first indian biotech company to receive us funding for proprietary technologies .
glentec international acquired the entire shareholding of unilever in bcz, bqil and biocon .
since its establishment, biocon foundation opened four arogya raksha yojana primary healthcare clinics. biocon foundation established a cancer hospital along with dr. devi shetty of narayana hrudayalaya
biocon grants exclusive license to ferozsons laboratories limited for marketing biomab egfr® in pakistan .
syngene international, a subsidiary of biopharmaceutical major biocon ltd, has ...
biopharmaceutical major biocon ltd has fixed the price band for the initial ...
bangalore - based biocon ltd, india’s largest biotechnology company founded by ...
biotechnology major biocon today said it is looking for partners to develop ...
biocon and iatrica partner to develop novel immunoconjugate therapeutics against cancer and infectious diseases .
biocon runs free oral cancer screens in india biocon organized a week of free oral cancer screening activities across 23 indian cities from september 1 - 7, 2014 .
because biocon story & potential (if at all) will unfold from 2019 .
biocon won the coveted award under the category of turnover above inr 500 crores .
if you are an investor who has shares of biocon ltd or you are an stock market analyst then i am sure you might for quarterly results of biocon ltd .
committed to creating a globally competitive biotech ecosystem in india through skill development, biocon ltd introduces biocon academy - a center of excellence for advanced learning in applied biosciences .
biopharmaceutical major biocon has set up an educational arm biocon academy with the objective of training and developing industryready talent for india' s $ 11 - billion biotech industry .
biocon was the first indian company to manufacture and export enzymes to usa and europe .
biocon began focusing on research and development, to develop novel enzymes for the biocon group worldwide through solid - state fermentation process technology referred to as
koji technology
.
biocon along with unit trust of india / technology development and investment corporation of india (uti / tdici), biocon biochemicals limited, ireland and others invested in bcz .
biocon grants exclusive license to ferozsons laboratories limited for marketing biomab egfr ® in pakistan .
biocon ranked at no. 6 among top 20 global biotech employers by the science magazine
biocon is ranked among the top 20 global biotechnology companies (med ad news) .
biocon is the 7th largest biotech employer in the world (med ad news) .
the company history page lists out the major events in chronological order for biocon ltd .
, the european union and european free trade association countries. biocon has exclusive rights for
mylan and biocon are exclusive partners on a broad portfolio of biosimilar and insulin products .
optimer taps biocon to supply commercial - scale api for c. difficile treatment | gen
biocon academy is a separate entity than biocon ltd. it is into the mission of training and developing industry - ready talent for the biopharma sector to enable global competitiveness .
biocon, advaxis to develop cancer immunotherapy against hpv biocon and advaxis will co - develop and commercialize adxs - hpv, a novel cancer immunotherapy for the treatment of hpv .
it was good expirence to do boicon. it cares more who works for biocon .
this is the third segment biocon would be addressing, after oncology and cardio diabetes .
2003—biocon becomes the first company worldwide to develop human insulin on a pichia expression system .
biocon recognized for its sfe digital initiative, in bfi conferred with digipharmax 2017 award .
biocon was honoured with the prestigious bio - pharma excellence award at bangalore technology summit .
biocon sa, the wholly owned subsidiary of bangalore - based biopharmaceuticals company biocon ltd, is acquiring around 49% stake in biocon biopharmaceuticals pvt ltd (bbpl) held by cimab sa, a cuban company. cimab sa was a joint venture partner with biocon, the company informed the stock exchange. the financial details of this transaction were undisclosed .
biocon received marketing authorization from the drugs controller general of india (dcgi) for its novel biologic itolizumab, anti cd6 molecule, for the treatment of chronic plaque psoriasis biocon enhances partnership with mylan through strategic collaboration for insulin products biocon delivers a healthy growth of 22% driven by strong traction in biopharma biocon launched alzumab ™ - a' first in class' novel biologic treatment for psoriasis patients in india biocon partnered with cytosorbents to market cytosorb ® - a' first - in - class' therapy for sepsis management biocon ranked at no. 6 among top 20 global biotech employers by the science magazine biocon unveils biocon academy - a center of excellence for advanced learning in applied biosciences biocon & mylan received indian regulatory approval for trastuzumab for treating breast cancer biocon and quark pharmaceuticals collaborate to develop novel sirna based therapeutics biocon' s alzumab ™ wins biospectrum biopharma product of the year, 2013 biocon academy' s flagship program in collaboration with kgi takes off to a flying start 2014 biocon has been conferred with the sir j c bose memorial award – 2013 (institutional category) by indian science monitor (ism) for its contribution in the field of biotechnology, with special reference to the launch of alzumab (itolizumab) biocon introduced canmab ™ - trastuzumab for treating breast cancer in india syngene, a subsidiary of biocon group, in collaboration with baxter sets up a dedicated research and development center at biocon park
bangalore: biopharmaceutical major biocon has set up an educational arm biocon academy with the objective of training and developing industryready talent for india' s $ 11 - billion biotech industry .
biocon acquired 99. 99% of syngene from its other shareholders, including icici venture and its affiliate funds, which divested their entire stake in syngene in exchange for issue of shares by biocon. syngene was made a 99. 99% subsidiary of biocon limited .
addressing media, kiran mazumdar - shaw, cmd, biocon said, that owing to capital expenditure requirements, biocon was monetising its investment in syngene. “at biocon, we have a large portfolio of biosimilars and need large capacity expansion and felt it justifiable to monetise the investment in syngene. it would allow biocon to tap into opportunities in regulated markets. ”
biocon ltd will announce its fy 2017 - 18 results in the month of april 2018 .
biocon disclosures under reg. 29 (1) of sebi (sast) regulations, 2011
biocon' s proprietary bioreactor christened plafractortm based on solid matrix fermentation received a u. s. patent. biocon commissioned its first fully automated submerged fermentation plant to produce specialty pharmaceuticals .
biocon announces the launch of its nephrology division and a comprehensive portfolio of renal therapy products .
1989 unilever plc. acquires biocon biochemicals ltd. in ireland and merges it with its subsidiary, quest international biocon is the first indian biotech company to receive us funding for proprietary technologies
biocon announced the launch of its nephrology division and a comprehensive portfolio of renal therapy products .
biocon has clocked another year of good performance, on the back of growth ...
syngene international, a subsidiary of biocon ltd, a generics major that also ...
the ipo is an offer for sale by biocon of a part of its shareholding in syngene. biocon, along with its subsidiary, biocon research holds 84. 5 per cent stake in syngene and post issue, this will come down to 74. 5 per cent .
people wrking with biocon always learn smart working. and very nice culture to work with .
2014 - biocon launched canmab, a new injectable drug for the treatment of a highly prevalent her2 - positive breast cancer. the drug has been jointly developed by biocon and us - based generic pharmaceutical major mylan and will be manufactured in biocon' s facility in bangalore .
biocon won the “unnatha suraksha puraskara” by national safety council (nsc), karnataka chapter .
biocon - kgi certificate program in biosciences biocon - kgi certificate program is biocon academy’s flagship program in biosciences. it is a' best - in - class' program that transforms graduate and post graduate students into professionals ready to take on the evolving challenges of the biotech industry .
2006 biocon inaugurates biocon biopharmaceuticals, india' s largest multi - product biologics facility at biocon park biocon inaugurates biocon park, india' s largest integrated biotechnology hub, comprising an integrated cluster of research laboratories and manufacturing facilities spread across 90 acres in kiadb (karnataka industrial areas development board) industrial estate. biocon announced a licensing agreement with bayer healthcare (bhc) for the exclusive marketing and trademark rights for insugen ® for the chinese market. syngene and innate pharmaceuticals ab, umea, sweden conclude a cooperation agreement to jointly develop, manufacture and market virulence blockers to counteract bacterial diarrhoeal disease. biocon launches india' s first anti - cancer drug biomab egfr ® .
biocon ltd will announce its q2 fy 2017 - 18 results in the month of october 2017 .
biocon ltd will announce its q3 fy 2017 - 18 results in the month of january 2018 .
biocon ltd will announce its q4 fy 2017 - 18 results in the month of april 2018 .
nov 29, 1978 - biocon’s founding day - the start of a biorevolution in india. biocon commenced operations as a joint venture between our promoter ms. kiran mazumdar - shaw and biocon biochemicals limited, an ireland based multinational. biocon began the manufacture and export of papain, a plant enzyme, and isinglass, a marine hydrocolloid, which are key products for the brewing industry .
the commercial success of biocon' s proprietary fermentation plant lead to a 3 - fold expansion .
biocon went for an ipo to raise rs 300 crores to fund its huge capital expansion plans .
biocon signs memorandum of understanding with deakin university, australia. to establish deakin research institute in bangalore
2009: biocon among top 20 indian companies in forbes? best under a billion? list .
biotech major biocon has tied up with cytosorbents, usa, to bring in a ...
ms kiran mazumdar - shaw, chairperson and managing director, biocon (file photo). —
ask a question about working or interviewing at biocon limited. our community is ready to answer .
biocon ltd. - manufacturer of biosimilars, insulin & mammalian cell culture in bengaluru, karnataka .
1993—biocon' s r & d and manufacturing facilities receive iso 9001 certification from rwtuv, germany .
kiran mazumdar - shaw, chairperson and managing director, biocon. photo: hemant mishra / mint
rakesh bamzai, president - marketing, biocon ltd, is leaving the company to ...
biocon foundation has developed and implemented a mobile phone based management platform for cancer... .
in the year 2000 the bioregio greifswald - rostock became biocon valley initiative. one year later first biocon valley mecklenburg - vorpommern e. v. , then biocon valley® gmbh were founded as central contact point for science and industry in the field of life science and health economy in mecklenburg - vorpommern. during this “bioregio period” biocon valley® was able to gather comprehensive experiences with publicly funded projects .
the 200, 000 sq ft biocon research center (brc) at biocon park will be equipped with capabilities in molecular biology, biologics process sciences, formulation research, and preclinical and clinical development .
biocon divests its stake in its german subsidiary, axicorp gmbh, to the existing group of promoter shareholders, axicorp was the licensee for biocon' s biosimilar insulin and glargine in germany and had the sole responsibility for commercializing these products. as a consequence of this divestment, these rights revert to biocon. biocon announced project commencement for first high - end biopharmaceutical manufacturing and r & d facility in bio - xcell, malaysia biocon launches insupen ®, a convenient and affordable reusable insulin delivery device 2012
in 2009, biocon launched basalog - long lasting basal insulin for type 1 & type 2 diabetics. during the year, the company inked partnership with isb to launch the biocon cell for innovation management. during the year, biocon announced strategic collaboration with mylan to enter the global generic biologics market .
2008 biocon acquires a 78% stake in german pharmaceutical company, axicorp gmbh for a consideration of €30 million biocon launches a safety device in the form of pre - filled syringes for two of its life saving products, gcsf (granulocyte - colony stimulating factor) and epo (erythropoietin) in collaboration with safety syringes inc. erypro safe ™ and nufil safe ™ are the first two drugs that will marketed using this novel device with other injectable products to follow in the future. biocon is ranked among the top 20 global biotechnology companies (med ad news). biocon is the 7th largest biotech employer in the world (med ad news). biocon announced the results of an ascending dose study on its oral insulin drug (in - 105) at the european association for the study of diabetes (easd) meeting in rome. 2009 biocon' s syngene partners with sapient discovery to expand integrated drug discovery offerings biocon' s syngene and dupont crop protection forge alliance partnership bristol - myers squibb and biocon' s syngene open new r & d facility at biocon park biocon launches basalog - long lasting basal insulin for type 1 & type 2 diabetics biocon inks partnership with isb to launch the biocon cell for innovation management biocon announced strategic collaboration with mylan to enter the global generic biologics market biocon limited and amylin pharmaceuticals entered into a global development and commercialization agreement for a novel peptide hybrid. the program will focus on the potential treatment of diabetes. biocon and hcg group of hospitals join hands to fight against cervical
uti / tdici transferred their entire shareholding in bcz to biocon limited, ireland. bcz commenced operations .
biocon signs memorandum of understanding with deakin university, australia. to establish deakin research institute in bangalore .
biocon divests its stake in its german subsidiary, axicorp gmbh, to the existing group of promoter shareholders, axicorp was the licensee for biocon' s biosimilar insulin and glargine in germany and had the sole responsibility for commercializing these products. as a consequence of this divestment, these rights revert to biocon .
2013: – biocon ranked at no. 6 among top 20 global biotech employers by the science magazine
unilever inks a deal with ici to sell its specialty chemicals division of which quest international is a part. unilever agrees to sell its shareholding in biocon to the indian promoters. biocon becomes an independent entity
unilever plc. acquires biocon biochemicals ltd. in ireland and merges it with its subsidiary, quest international
biocon - mylan' s breast cancer biosimilar gets thumbs - up from usfda' s ...
health care: through its integrated health care initiatives, biocon foundation is constantly engaged... .
dr. kiran mazumdar shaw established biocon foundation in 2004. biocon foundation' s vision is to promote social and economic inclusion by ensuring that marginalized communities have equal access to healthcare services and educational opportunities .
in 2016, mylan and biocon announced usfda submission for proposed biosimilar trastuzumab. mylan and biocon also announced that regulatory submission for insulin glargine and proposed biosimilar pegfilgrastim were accepted for review by european medicines agency. during the year, biocon launched its insulin glargine in japan. during the year, biocon and quark announced initiation of pivotal phase ii / iii study of qpi - 1007 in rare eye disease in india. during the year, biocon received its first generic formulation approval in european union. also during the year, biocon signed co - development & commercialization agreement with lab pisa for rh - insulin in usa .
a year later, biocon entered the european market by acquiring a 70 percent stake in german pharmaceutical company, axicorp gmbh. says dr kiran mazumdar shaw, chairman and managing director of biocon, “axicorp is a key strategic investment for biocon as it heralds our european foray for biosimilars like recombinant human insulin. ”
local firms that have worked with biocon include san diego' s sapient discovery, which partnered with biocon' s subsidiary syngene international to provide a full array of drug discovery services, and invitrogen – now known as life technologies – which signed a deal in 2007 to market biocon' spharmaceutical - grade insulin .
biocon targets the rh - insulin opportunity in the us by collaborating with lab pisa, its long standing partner in mexico. pursuant to this, biocon has recorded an exceptional income of rs 268 cr on account of the changes in the nature of biocon' s future obligations on the rh - insulin program .
biocon inaugurated biocon park, india' s largest integrated biotechnology hub, comprising an integrated cluster of research laboratories and manufacturing facilities spread across 90 acres in kiadb (karnataka industrial areas development board) industrial estate .
1998 unilever inks a deal with ici to sell its specialty chemicals division of which quest international is a part. unilever agrees to sell its shareholding in biocon to the indian promoters. biocon becomes an independent entity
biocon inaugurates biocon park, india' s largest integrated biotechnology hub, comprising an integrated cluster of research laboratories and manufacturing facilities spread across 90 acres in kiadb (karnataka industrial areas development board) industrial estate .
pincode of syngene international pvt ltd bsez – s11 unit ii, biocon special economic zone, biocon park, plot no. 2 & 3, bommasandra industrial area iv phase, bommasandra jigani link road, bangalore
in addition to its herceptin biosimilar, the march inspection was also for mylan' s and biocon’s biosimilar of amgen’s neulasta and the pen assembly for some of the insulin products biocon intends to launch in europe .
as part of the collaboration, biocon would make an equity investment in vaccinex and both the companies would jointly work to identify at least four therapeutic antibody products, biocon informed the bombay stock exchange on thursday .
we are delighted to announce this partnership as vaccinex has a strong discovery - led platform that will be beneficial to biocon ,
kiran mazumdar - shaw, chairman and managing director, biocon, said .
2009—syngene partners with sapient discovery to expand integrated drug discovery offerings; syngene and dupont crop protection forge alliance partnership; bristol - myers squibb and syngene open new r & d facility at biocon park; biocon launches basalogtm – long lasting basal insulin for type 1 & type 2 diabetics; biocon inks partnership with isb to launch the biocon cell for innovation management; announces strategic collaboration with mylan to enter the global generic biologics market; biocon and amylin pharmaceuticals enter into a global development and commercialisation agreement for a novel peptide hybrid .
biocon acquired the entire shareholding of bcz, bqil & hlx from glentec international, ms. kiran mazumdar - shaw and others in exchange for issue of shares by biocon. biocon became an independent entity glentec international acquired a majority stake (approx 64 %) in syngene as part of a fresh issue of shares .
2011 - biocon divests its stake in its german subsidiary, axicorp gmbh, to the existing group of promoter shareholders, axicorp was the licensee for biocon' s biosimilar insulin and glargine in germany and had the sole responsibility for commercializing these products. as a consequence of this divestment, these rights revert to biocon .
unilever plc. acquired biocon biochemicals ltd. in ireland and merged it with its subsidiary, quest international .
clinigene was incorporated to conduct longitudinal clinical studies in select disease segments as a wholly owned subsidiary of biocon .
biocon acquires a 78% stake in german pharmaceutical company, axicorp gmbh for a consideration of €30 million .
2005 biocon signs a commercial agreement for supply of insulin api to asia, africa and the middle east .
biocon explores investment in malaysia in partnership with biotechcorp biocon and bayer join hands to create awareness for self monitoring for diabetics syngene and endo pharmaceuticals, usa to jointly discover and develop novel biological drug molecules to fight cancer biocon acquires stake of its cuban partner cimab s. a. in their seven year old jv, biocon biopharmaceuticals pvt. ltd biocon and optimer pharmaceuticals announce manufacturing and supply agreement for a novel api, first - in - class anti - infective (c. difficile) biocon and the center of molecular immunology (cim), based in havana, cuba strengthen their existing research partnership by joining forces for an integrated antibody program in immunology biocon announced a strategic foreign direct investment in malaysia with the malaysian biotechnology corporation sdnbhd (biotechcorp )
1998: unilever inks a deal with ici to sell its specialty chemicals division of which quest international is a part. unilever agrees to sell its shareholding in biocon to the indian promoters. biocon becomes an independent entity
the ruling by the apex court, however, may not result in a big adverse impact for biocon .
biocon today is india’s biggest biotech company. kiran mazumdar - shaw started out brewing enzymes in her garage .
abraxis bioscience, inc. and biocon limited announce approval of abraxane in india for the treatment of breast cancer
under this agreement, abraxis would receive royalties from biocon based on net sales of abraxane in these countries .
source: biocon. disclaimer: this article does not necessarily reflect the views of asianscientist or its staff .
biocon limited to build us $ 161 million r & d facility in bio - xcell, malaysia indian biotech company biocon limited will build a biopharmaceutical manufacturing and r & d; facility in iskandar malaysia, johor .
biocon diabetology - service provider of insulin - insugen, metadoze - ipr & trigpm in bengaluru, karnataka .
ver the last 5 years biocon healthcare has emerged as a significant player in the anti - diabetic market. today, biocon is perceived as a dependable partner in managing diabetes by offering high quality products and services .
indian biopharmaceutical company biocon has teamed up with jdrf to test oral insulin on people with type 1 diabetes .
biocon foundation tries to plug the gap in math education through the chinnara ganitha math workbook... .
delivering on its commitment to affordable healthcare, biocon foundation has been setting up ary cli... .
optimer pharmaceuticals and biocon inked a long - term supply agreement for the commercial manufacturing of fidaxomicin, optimer' s lead candidate for the treatment of clostridium difficile infection (cdi). biocon' s expertise in fermentation technology and the team' s prior analytical development work with fidaxomicin prompted optimer to enter this arrangement with biocon .
bbpl (biocon biopharmaceuticals private limited) was incorporated to manufacture and market a select range of biotechnology based life saving drugs as a 51: 49 joint venture with cimab (cuban centre of molecular immunology) and biocon .
pincode of syngene international pvt ltd bsez – s11 unit ii, biocon special economic zone, biocon park, plot no. 2 & amp; 3, bommasandra industrial area iv phase, bommasandra jigani link road, bangalore
ms. mazumdar - shaw said biocon could consider de - merging syngene in future. “that could happen only when biocon moves into bigger markets. it will certainly not happen for the next 3 - 4 years. ”
examples of how biocon puts the ip - partnership philosophy into practice are multiplying. take, for instance, the recent partnership between biocon and vaccinex inc. of new york, to take forward biocon’s search for antibodies for use in immunotherapy - based cancer treatment. the companies are now jointly developing novel, fully human antibodies, by combining vaccinex’s patented technology for generating human antibodies with biocon’s expertise in clinical research and manufacture of biologics. biocon has forged similar partnerships with companies and research institutes as far away as cuba and scotland in the united kingdom .
november 29, 1978 biocon’s founding day - the start of a biorevolution in india. over the years, biocon has evolved from an enzyme - manufacturing company into a fully integrated biopharmaceutical enterprise. today, we leverage a formidable combination of proprietary fermentation technologies and research skills to develop affordable therapy for unmet medical needs. biocon india is incorporated as a joint venture between biocon biochemicals ltd. of ireland and an indian entrepreneur, kiran mazumdar - shaw
biocon limited, signed a commercial agreement for supply of insulin api in asia, africa and the middle east .
1989: unilever plc. acquires biocon biochemicals ltd. in ireland and merges it with its subsidiary, quest international
2005: biocon signs a commercial agreement for supply of insulin api to asia, africa and the middle east .
biocon and optimer pharmaceuticals announce manufacturing and supply agreement for a novel api, first–in–class anti–infective (c. difficile )
p ortuguese investment bank espirito santo has raised concerns over the accounting processes of bangalore - based biotechnology company biocon .
there is absolutely neither any governance issue nor any accounting issue. biocon has always adopted a very transparent reporting practice and has taken full care to ensure we are in compliance ,
biocon said in an email response .
cmd of biocon. she said two - three such contract research manufacturing agreements were presently underway at the company .
it also expected a larger share of the rs. 125 crore immunosuppressants market, which biocon was already into .
biocon' s insulin glargine becomes the first biosimilar from india and 2nd biosimilar glargine to be approved in japan .
biocon' s quarterly consolidated revenue crosses the rs 1, 000 cr milestone for the first time in q4fy16 .
concerned over the lack of industry - ready graduates in the biotech sector, biocon has launched its own academy .
silver leaf oak (mauritius) limited, an investment vehicle advised by india value fund advisors has agreed to acquire a minority 10% stake in syngene international limited, biocon' s research services subsidiary. silver leaf will acquire the stake from biocon research limited, a wholly owned subsidiary of biocon limited at a valuation of rs. 3800 crore
in 2013, biocon received marketing authorization from the drugs controller general of india (dcgi) for its novel biologic itolizumab, anti cd6 molecule, for the treatment of chronic plaque psoriasis. during the year, biocon expanded its partnership with mylan through strategic collaboration for insulin products. in 2013, biocon launched alzumab - a first in class novel biologic treatment for psoriasis patients in india. during the year, biocon partnered with cytosorbents to market cytosorb - a first - in - class therapy for sepsis management. during the year, biocon and mylan received indian regulatory approval for trastuzumab for treating breast cancer. in 2013, biocon and quark pharmaceuticals announced collaboration to develop novel sirna based therapeutics .
2004—day 1 on the bourses closes with a market value of $ 1. 11 billion, making biocon only the second indian company to cross the $ 1 billion mark on the first day of listing; syngene establishes new research centre; biocon launches insugen; biocon partners with vaccinex to discover and co - develop at least four therapeutic antibody products .
2011: biocon divests its stake in its german subsidiary, axicorp gmbh, to the existing group of promoter shareholders .
abraxis bioscience, inc. and biocon limited announce approval of abraxane in india for the treatment of breast cancer | biospace
indian pharmaceutical company, biocon, announced on thursday the inauguration of its new integrated r & d center in bangalore .
biocon shares on tuesday closed at rs442. 15 apiece on bse, down 0. 89% from previous close .
biocon has five key verticals—small molecules (apis), biosimilars, branded formulations, novel molecules and research services. it is also into cro through syngene and clinical trials through clinigene besides a drug discovery and development research arm biocon research .
sets up a dedicated nutrition research and development center at biocon park in a collaboration between abbott and syngene international ltd .
until the drug product facility gets clearance, biocon will not get marketing approval for its biosimilars in the european market .
2006—inaugurates biocon biopharmaceuticals, india' s largest multi - product biologics facility at biocon park; inaugurates biocon park, india' s largest integrated biotechnology hub; licensing agreement with bayer healthcare (bhc) for the exclusive marketing and trademark rights for insugen for the chinese market; syngene signs a cooperation agreement with innate pharmaceuticals to jointly develop, manufacture and market virulence blockers to counteract bacterial diarrhoeal disease; biocon launches india' s first anti - cancer drug, biomab egfr .
biocon also have research focus in bio - technology and is one of the largest bio - tech company in india .
biocon’s corporate communications team has been ranked at no. 13 amongst top 30 teams in india by reputation today magazine .
kiran mazumdar - shaw, cmd, biocon, said: “early detection of cervical cancer through biocon foundation' s screening program has led to early treatment at lower cost and greatly enhanced treatment outcomes in the rural communities we serve. ”
the first batch will start off with 25 students and biocon has plans to train 100 students in the first year .
biocon academy certificate program in faculty development biocon academy has introduced faculty development program a first - of - its - kind initiative to empower biotech faculty from various educational institutes by helping them upgrade their knowledge of emerging industry - specific technologies. it is a unique program which is aimed at the faculty who are teaching biotechnology. it is a 2 - weeks full - time program, delivered at the biocon academy which comprises of 20 interactive lectures delivered by subject matter experts from biocon and 24 hours of experiential learning at biocon’s high - end and world class manufacturing facilities, quality and research labs .
biocon and bayer join hands to create awareness for self - monitoring for diabetics syngene and endo pharmaceuticals, usa to jointly discover and develop novel biological drug molecules to fight cancer biocon acquires stake of its cuban partner cimab s. a. in their seven - year - old jv, biocon biopharmaceuticals pvt. ltd biocon and optimer pharmaceuticals announce manufacturing and supply agreement for a novel api, first - in - class anti - infective (c. difficile) biocon and the center of molecular immunology (cim), based in havana, cuba strengthen their existing research partnership by joining forces for an integrated antibody program in immunology biocon announces a strategic foreign direct investment in malaysia with the malaysian biotechnology corporation sdnbhd (biotechcorp )
while, biocon academy would certainly like to accept applications from the phd candidates who wish to pursue the biocon - kgi program, the recruiters who visit our campus for the recruitment program find it difficult to meet career aspirations of these candidates .
2017 u. s. fda accepts biologics license application (bla) for mylan and biocon' s proposed biosimilar pegfilgrastim for review biocon started commercial operations at its malaysia facility with the myr 300 million contract from moh, malaysia to supply rh - insulin u. s. fda accepts biologics license application (bla) for mylan and biocon' s proposed biosimilar trastuzumab
biocon ltd (bse code: 532523, nse: biocon), asia' s premier biopharmaceuticals company, today announced that its contract research subsidiary syngene international ltd (“syngene”) has filed the draft red herring prospectus (drhp) with the securities and exchange board of india (sebi) on april 22, 2015, seeking approval for an initial public offering (ipo). this is an offer for sale (ofs) by biocon of a part of its shareholding in syngene. biocon along with its subsidiary biocon research limited (brl) currently holds an 84. 5% equity stake in syngene .
in 2010, biocon and bayer joined hands to create awareness for self monitoring for diabetics. during the year, biocon acquired the stake of its cuban partner cimab s. a. in their seven year old jv, biocon biopharmaceuticals pvt. ltd. in 2010, biocon and optimer pharmaceuticals announced manufacturing and supply agreement for a novel api, first - in - class anti - infective (c. difficile). during the year, biocon and the center of molecular immunology (cim), based in havana, cuba strengthened their existing research partnership by joining forces for an integrated antibody program in immunology. during the year, biocon announced a strategic foreign direct investment in malaysia with the malaysian biotechnology corporation sdnbhd (biotechcorp) .
biocon ltd will announce its q1 fy 2017 - 18 results in august 2017. will soon update the below mentioned table .
careers at biocon - all our employees are critical contributor in improving the state of global healthcare, by delivering affordable innovation .
biocon limited and vaccinex, inc. announce a broad strategic partnership to discover and co–develop at least four therapeutic antibody products .
syngene enters into a research partnership with bristol–myers squibb and completes the ground breaking ceremony of new research facility at biocon park .
# highlightinvestment today # option and # biocon news option call: buy biocon 600 put above 15. 00 targets 17. 00 / 20. 00 / 24. 00 stoploss 11. 50 get # intradaycashtips and 7 days free trial: -
with this programme on hold, biocon is aggressively progressing on its four other molecule programs addressing diabetes, oncology and psoriasis .
mr rakesh bamzai, president – marketing, biocon, said the rs 80 - 100 crore domestic market for taxanes was alarmingly heading towards double the size in the next three years. biocon expected to earn rs 10 crore in the first year .
welcome to biocon' s press room. here we feature a comprehensive press kit, news updates, press releases, brochures and other media resources. this section has been designed to provide reporters easy access to all the information needed on biocon .
biocon limited is listed on the national stock exchange of india (nse) and the mumbai stock exchange (bse) .
1978 – founded by indian entrepreneur, ms. kiran mazumdar - shaw, as a joint venture with biocon biochemicals ltd .
biocon is a good house to work. and i have enjoyed a lot at the time of insupen launching ...
chairperson and managing director of biocon, kiran mazumdar - shaw, said with the launch of the new products, biocon anticipated a 25 per cent market share of the renal disease related medications market, estimated to be around rs. 300 crore .
1996—the commercial success of biocon' s proprietary fermentation plant leads to a 3 - fold expansion; enters biopharmaceuticals and statins .
2013 will be an exciting year for the company as biocon prepares to introduce its’ second novel molecule, itolizumab – an anti cd6 monoclonal antibody for psoriasis in india. this will hugely benefit the patients and will be an important milestone for biocon .
biocon received the award under the category of ‘leveraging technology for use of both digital and onsite promotion for integrated digital marketing’ .
biocon ranked 09 among global biotech employers for 2017 by science magazine. the only asian company to feature in top 20 .
biocon was conferred with the ´the star exporter award´ by the federation of karnataka chambers of commerce & industry (fkcci) .
admission requests for the biocon - kgi certificate program in biosciences will be accepted online. please follow the below application process :
biocon foundation was established with the aim of identifying and implementing projects that will impact the social and economic scenario in the country. biocon foundation launched arogya raksha yojana, a unique micro - health insurance scheme for rural india in association with narayana hrudayalaya .
it has also expanded its global footprint to emerging and developed markets through acquisitions, partnerships and in - licensing. biocon’s corporate social responsibility wing, the biocon foundation, is involved in numerous health and education outreach programs targeting the underprivileged sections of india .
biocon during early 2008 had formed a strategic partnership including an investment in iatrica to develop a new class of immunoconjugates for targeted immunotherapy of cancers and infectious diseases. the companies were supposed to co - develop candidate products based upon iatrica’s technology platform and biocon’s expertise in drug development, biologics manufacturing, and clinical research. biocon has since provisioned for dimunition of its investment in iatrica .
about biocon established in 1978, biocon limited is one of india' s premier biotechnology companies. biocon and its two subsidiary companies, syngene international ltd and clinigene international ltd form a fully integrated biotechnology enterprise, specializing in biopharmaceuticals, custom research and clinical research. with successful initiatives in clinical development, bio - processing and global marketing, biocon delivers products and solutions to partners and customers across the globe. many of these products have usfda and emea acceptance. biocon launched the world' s first recombinant human insulin, insugen ® in november 2004 using pichia expression and india' s first indigenously produced monoclonal antibody biomab - egfr ™ .
bse code: 532523 nse symbol: biocon isin no. : ine376g01013 industry: biotechnology face value: rs. 5. 00
biocon limited, announces the launch of insugen®, the new generation bio–insulin, manufactured in asia' s largest human insulin plant .
biocon’s german subsidiary axicorp gmbh, which sells generic drugs in the local market, saw sales drop by 16% , over the year - ago period, to rs 218 crore. it contributed about 36% to biocon’s sales in the first three quarters .
according to neopharma and biocon, neobiocon will be established in dubai, uae. the company will provide medicines to that country .
amylin and biocon announced thursday that they would develop, commercialize and manufacture the drug using amylin’s peptide hybrid, or “phybrid” technology .
cutting - edge: sections of the new lab that biocon inaugurated in bangalore in 2012 to do more biologics research and development .
biocon has also dedicated a research wing at brc in honor of prof. rao, which was also unveiled on the occasion .
and bristol - myers squibb (bms) have extended their collaboration for the next five years, biocon said in a statement .
mylan and biocon’s proposed biosimilar trastuzumab is also under review by regulatory authorities in australia, canada, europe and several emerging markets .
restructuring of legal entities biocon has restructured its legal entities to align with its growth strategies represented by its strategic business units. we believe this restructuring will enable us to unlock greater value from our business segments at an opportune time. all our biosimilar assets will now be consolidated under the new legal entity, biocon biologics limited incorporated in uk as a subsidiary of biocon limited, india .
the excellent l & d; initiatives at biocon has contributed to the company being ranked amongst the global top 10 biotech employers .
biocon foundation also aims to develop the pure sciences and experiential scientific learning by supporting organizations that are engaged in path breaking projects .
the asia best csr practices awards recognize corporates in asia that have had a significant and positive impact on people, communities and the environment. s. raman, vice president & head of biocon malaysia operations, received the award on behalf of biocon foundation .
signage for biocon ltd. is displayed at the company’s campus in bengaluru, india. (photographer: dhiraj singh / bloomberg )
in this article you will find q1, q2, q3, q4 and fy 2017 - 18 results of biocon ltd. that’s not all, you can compare those results with previous year i. e. , fy 2016 - 17 results of biocon ltd .
biocon said (pdf) in a filing sunday that the european medicines agency found issues with its product plant in banglore and has told them a follow - up inspection will be required to insure biocon implemented changes before the ema will give it a thumbs up .
, biocon has two subsidiaries— syngene, a custom research organisation, and clinigene, a clinical research organisation. biocon’s presence straddles four main therapeutic areas—diabetology, cardiology, nephrology and oncology— and plans to introduce two new divisions, comprehensive care, and immunotherapy, this year
biocon foundation biocon foundation’s initiatives are primarily focused on healthcare, primary education and civic infrastructure. all projects are developed and implemented by biocon foundation based on need assessment through discussions with local communities, and government departments. project appraisals are done periodically by combining community feedback with evaluation metrics developed by the foundation. these metrics include patient footfall, health indicators, feedback from teachers, community satisfaction etc .
in 2014, biocon introduced canmab - trastuzumab for treating breast cancer in india. during the year, silver leaf oak (mauritius) limited, an investment vehicle advised by india value fund advisors agreed to acquire a minority 10% stake in syngene international limited, biocons research services subsidiary. silver leaf will acquire the stake from biocon research limited, a wholly owned subsidiary of biocon limited at a valuation of rs 3800 crore. during the year, biocon expanded its strategic partnership with cytosorbents to treat sirs and cardiac surgery patients .
biocon scaled up its in - house research programme, based on a proprietary solid substrate fermentation technology, from pilot to plant level .
biocon limited and vaccinex, inc. announced a broad strategic partnership to discover and co - develop at least four therapeutic antibody products .
syngene enters into a research partnership with bristol - myers squibb and completes the ground breaking ceremony of new research facility at biocon park .
biocon and neopharma sign an mou to establish neobiocon, a joint venture company in dubai' s biotechnology and research park, dubiotech .
biocon and neopharma sign an mou to establish neobiocon, a joint venture company in dubai' s biotechnology and research park, dubiotech .
biocon announces a licensing agreement with bayer healthcare (bhc) for the exclusive marketing and trademark rights for insugen® for the chinese market .
biocon ltd said it would buy out the 49 per cent equity stake of its cuban partner cimab s. a. in their seven - year - old joint venture, biocon biopharmaceuticals p ltd. its note to the bourses did not disclose payment and other details .
biocon limited and vaccinex, inc. announce a broad strategic partnership to discover and co - develop at least four therapeutic antibody products .
the extension follows biocon’s withdrawal of its application for approval for trastuzumab and pegfilgrastim, a drug used to fight infections in chemotherapy patients .
“this three - month extension has no impact on the anticipated timetable for commercialization of this product in the us, ” biocon said .
gaining confidence: arun chandavarkar, ceo and joint md, biocon, says a disproportionate amount of funds are being deployed in biopharma .
the certificate program is offered by biocon academy in association with keck graduate institute, which is a registered institute under the us law .
in january, biocon had sold 10 per cent stake in syngene for rs. 380 crore to private equity fund silver leaf oak .
sets up a dedicated r & d center at biocon park through a collaboration between its subsidiary, syngene international ltd. , and baxter
rs 300 crore currently. biocon has targetted to capture 25 per cent of the marketshare in india in five years, he said .
* mention of
biosimilar trastuzumab
refers to biocon' s global programs and has no reference to the indian sub - continent .
on january 12, 2015, biocon research limited (a wholly owned subsidiary of biocon) transferred a 10% stake in syngene to ivf trustee company private limited, sole trustee of india value fund iv, for a consideration of rs. 3, 800 million .
biocon was honoured with the prestigious idma corporate citizen award 2017 at the 56th annual day celebrations of the indian drug manufacturers' association .
our philosophy as a socially responsible corporate, biocon acknowledges its responsibility towards the environment, its consumers, employees, and other stakeholders .
dr. arun chandavarkar, ceo and joint managing director, biocon said :
the european approval for biocon’s generic version of rosuvastatin calcium underscores biocon’s unique strengths in the chronic therapies space and our compliance with global standards that enable us to achieve the highest quality standards for all our products. it augurs well for this nascent business, which will be one of our growth drivers in the coming years .
in 2011, biocon sold its stake in its german subsidiary, axicorp gmbh, to the existing group of promoter shareholders. axicorp was the licensee for biocons biosimilar insulin and glargine in germany and had the sole responsibility for commercializing these products. as a consequence of this divestment, these rights revert to biocon. in 2011, biocon announced project commencement for first high - end biopharmaceutical manufacturing and r & d; facility in bio - xcell, malaysia. during the year, biocon launched insupen, a convenient and affordable reusable insulin delivery device. in 2012, biocon announced positive results from its global phase 3 study with recombinant human insulin. during the year, ge capital announced investment in syngene, biocons research services subsidiary. during the year, biocon announced positive efficacy data from phase 3 clinical study with its novel monoclonal antibody, itolizumab for psoriasis. biocon also announced positive results from its phase 1 comparative pk - pd study with biosimilar insulin glargine. during the year, biocon entered into an agreement with bristol - myers squibb for its in - 105, an oral insulin drug.
biocon limited ( bse : 532523 ) is an indian biopharmaceutical company based in bangalore , india . the company manufactures generic active pharmaceutical ingredients ( apis ) that are sold in the developed markets of the united states and europe . it also manufactures biosimilar insulins , which are sold in india as branded formulations and in both bulk and formulation forms . in research services , syngene international limited ( syngene ) is engaged in the business of custom research in drug discovery while the other fully owned subsidiary clinigene international limited ( clinigene ) is in the clinical development space . in december 2009 , biocon acquired the active pharma ingredients ( api ) undertaking from idl speciality chemicals ltd. , a subsidiary of gulf oil corporation limited . located with r&d in bangalore and api unit in hyderabad , india , biocon has two subsidiaries — syngene , a custom research organisation , and clinigene , a clinical research organisation . biocon ’s presence straddles four main therapeutic areas — diabetology , cardiology , nephrology and oncology — and plans to introduce two new divisions , comprehensive care , and immunotherapy , this year . biocon ’s cardiology , nephrology , diabetology and oncology products including bestor , basalogtm , biomab egfr , statix , nufil safe , insugen , tacrograf , erypro safe , and myokinase are claimed to be considerably less expensive than other leading brands . two of its novel programs on the verge of proof-of-concept stage are in-105 , which is the only oral insulin in the world to be in long duration clinical trials , and t1h , a novel humanised monoclonal antibody ( mab ) , the only first-in-class novel mab being tested in india for rheumatoid arthritis and psoriasis . between 2005 and 2010 , biocon entered into more than 2,200 high-value r&d licensing and other deals within the pharmaceuticals and bio-pharmaceutical space . it has also expanded its global footprint to emerging and developed markets through acquisitions , partnerships and in-licensing . biocon ’s corporate social responsibility wing , the biocon foundation , is involved in numerous health and education outreach programs targeting the underprivileged sections of india . in 2009 – 10 , biocon ’s net income increased 44 % to ₹ 24.048 billion ( us$ 370 million ) , crossing the half-billion-dollar mark and profits grew 215 % to ₹ 2.933 billion ( us$ 46 million ) . the pharmaceutical business exceeded ₹ 200.871 billion ( us$ 3.1 billion ) in revenue and the net r&d expenditure increased to ₹ 917 million ( us$ 14 million ) , growing 42 % over 2008 and up 282 % over 2005 , while its research services business crossed ₹ 2.807 billion ( us$ 44 million ) . biocon , syngene and clinigene together employ approximately 4,500 personnel including biologists , chemists , medical practitioners , pharmacologists , engineers , finance/legal/marketing analysts , hr generalists and general administrators . around 6 % of its employees have phd degrees , 45 % have a master 's degree , and 33 % are graduates . biocon also collaborates with educational institutes to make courses more industry oriented . 
biocon limited (bse: 532523) is an indian biopharmaceutical company based in bangalore, india. the company manufactures generic active pharmaceutical ingredients (apis) that are sold in the developed markets of the united states and europe. it also manufactures biosimilar insulins, which are sold in india as branded formulations and in both bulk and formulation forms. in research services, syngene international limited (syngene) is engaged in the business of custom research in drug discovery while the other fully owned subsidiary clinigene international limited (clinigene) is in the clinical development space. in december 2009, biocon acquired the active pharma ingredients (api) undertaking from idl speciality chemicals ltd., a subsidiary of gulf oil corporation limited. located with r&d in bangalore and api unit in hyderabad, india, biocon has two subsidiaries — syngene, a custom research organisation, and clinigene, a clinical research organisation. biocon ’s presence straddles four main therapeutic areas — diabetology, cardiology, nephrology and oncology — and plans to introduce two new divisions, comprehensive care, and immunotherapy, this year. biocon ’s cardiology, nephrology, diabetology and oncology products including bestor, basalogtm, biomab egfr, statix, nufil safe, insugen, tacrograf, erypro safe, and myokinase are claimed to be considerably less expensive than other leading brands. two of its novel programs on the verge of proof-of-concept stage are in-105, which is the only oral insulin in the world to be in long duration clinical trials, and t1h, a novel humanised monoclonal antibody (mab), the only first-in-class novel mab being tested in india for rheumatoid arthritis and psoriasis. between 2005 and 2010, biocon entered into more than 2,200 high-value r&d licensing and other deals within the pharmaceuticals and bio-pharmaceutical space. it has also expanded its global footprint to emerging and developed markets through acquisitions, partnerships and in-licensing. biocon ’s corporate social responsibility wing, the biocon foundation, is involved in numerous health and education outreach programs targeting the underprivileged sections of india. in 2009 – 10, biocon ’s net income increased 44% to ₹ 24.048 billion (us$ 370 million), crossing the half-billion-dollar mark and profits grew 215% to ₹ 2.933 billion (us$ 46 million). the pharmaceutical business exceeded ₹ 200.871 billion (us$ 3.1 billion) in revenue and the net r&d expenditure increased to ₹ 917 million (us$ 14 million), growing 42% over 2008 and up 282% over 2005, while its research services business crossed ₹ 2.807 billion (us$ 44 million). biocon, syngene and clinigene together employ approximately 4,500 personnel including biologists, chemists, medical practitioners, pharmacologists, engineers, finance/legal/marketing analysts, hr generalists and general administrators. around 6% of its employees have phd degrees, 45% have a master's degree, and 33% are graduates. biocon also collaborates with educational institutes to make courses more industry oriented.
biocon limited (bse: 532523) is an indian biopharmaceutical company based in bangalore, india. the company manufactures generic active pharmaceutical ingredients (apis) that are sold in the developed markets of the united states and europe. it also manufactures biosimilar insulins, which are sold in india as branded formulations and in both bulk and formulation forms. in research services, syngene international limited (syngene) is engaged in the business of custom research in drug discovery while the other fully owned subsidiary clinigene international limited (clinigene) is in the clinical development space. in december 2009, biocon acquired the active pharma ingredients (api) undertaking from idl speciality chemicals ltd., a subsidiary of gulf oil corporation limited. located with r&d in bangalore and api unit in hyderabad, india, biocon has two subsidiaries — syngene, a custom research organisation, and clinigene, a clinical research organisation. biocon ’s presence straddles four main therapeutic areas — diabetology, cardiology, nephrology and oncology — and plans to introduce two new divisions, comprehensive care, and immunotherapy, this year. biocon ’s cardiology, nephrology, diabetology and oncology products including bestor, basalogtm, biomab egfr, statix, nufil safe, insugen, tacrograf, erypro safe, and myokinase are claimed to be considerably less expensive than other leading brands. two of its novel programs on the verge of proof-of-concept stage are in-105, which is the only oral insulin in the world to be in long duration clinical trials, and t1h, a novel humanised monoclonal antibody (mab), the only first-in-class novel mab being tested in india for rheumatoid arthritis and psoriasis. between 2005 and 2010, biocon entered into more than 2,200 high-value r&d licensing and other deals within the pharmaceuticals and bio-pharmaceutical space. it has also expanded its global footprint to emerging and developed markets through acquisitions, partnerships and in-licensing. biocon ’s corporate social responsibility wing, the biocon foundation, is involved in numerous health and education outreach programs targeting the underprivileged sections of india. in 2009 – 10, biocon ’s net income increased 44% to ₹ 24.048 billion (us$ 370 million), crossing the half-billion-dollar mark and profits grew 215% to ₹ 2.933 billion (us$ 46 million). the pharmaceutical business exceeded ₹ 200.871 billion (us$ 3.1 billion) in revenue and the net r&d expenditure increased to ₹ 917 million (us$ 14 million), growing 42% over 2008 and up 282% over 2005, while its research services business crossed ₹ 2.807 billion (us$ 44 million). biocon, syngene and clinigene together employ approximately 4,500 personnel including biologists, chemists, medical practitioners, pharmacologists, engineers, finance/legal/marketing analysts, hr generalists and general administrators. around 6% of its employees have phd degrees, 45% have a master's degree, and 33% are graduates. biocon also collaborates with educational institutes to make courses more industry oriented.